The serum fascin-1 and tumor components containing this protein in patients with head and neck squamous cell carcinoma: A pilot study

Gelena V. Kakurina; Elena E. Sereda; Marina N. Stakheeva; Liubov Tashireva; Olga V. Cheremisina; Irina V. Kondakova; Evgeny L. Choinzonov

doi:10.7555/JBR.38.20240397

Journal of Biomedical Research ›› 2025, Vol. 39 ›› Issue (5) :534 -537. DOI: 10.7555/JBR.38.20240397

Letter to the Editor

research-article

The serum fascin-1 and tumor components containing this protein in patients with head and neck squamous cell carcinoma: A pilot study

Author information +

History +

PDF (2348KB)

Cite this article

Download citation ▾

Gelena V. Kakurina, Elena E. Sereda, Marina N. Stakheeva, Liubov Tashireva, Olga V. Cheremisina, Irina V. Kondakova, Evgeny L. Choinzonov. The serum fascin-1 and tumor components containing this protein in patients with head and neck squamous cell carcinoma: A pilot study. Journal of Biomedical Research, 2025, 39(5): 534-537 DOI:10.7555/JBR.38.20240397

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Wahab A, Hyytiäinen A, Wahbi W, et al. The effect of fascin 1 inhibition on head and neck squamous cell carcinoma cells[J]. Eur J Oral Sci, 2021, 129(6): e12819. doi: 10.1111/eos.12819

[2]	Sulaiman A, Yao Z, Wang L. Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression[J]. J Biomed Res, 2018, 32(2): 81-90. doi: 10.7555/JBR.31.20160124

[3]	Lin D, Shen L, Luo M, et al. Circulating tumor cells: Biology and clinical significance[J]. Signal Transduct Target Ther, 2021, 6(4): 404. doi: 10.1038/s41392-021-00817-8

[4]	Gires O, Pan M, Schinke H, et al. Expression and function of epithelial cell adhesion molecule EpCAM: Where are we after 40 years?[J]. Cancer Metastasis Rev, 2020, 39(3): 969-987. doi: 10.1007/s10555-020-09898-3

[5]	Kakurina GV, Kondakova IV, Spirina LV, et al. Expression of genes encoding cell motility proteins during progression of head and neck squamous cell carcinoma[J]. Bull Exp Biol Med, 2018, 166(2): 250-252. doi: 10.1007/s10517-018-4325-1

[6]	Kasradze D, Juodzbalys G, Guobis Z, et al. Genetic and proteomic biomarkers of head-and-neck cancer: A systematic review[J]. J Cancer Res Ther, 2020, 16(3): 410-424. doi: 10.4103/jcrt.JCRT_145_17

[7]	Weller P, Nel I, Hassenkamp P, et al. Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC)[J]. PLoS One, 2014, 9(12): e113706. doi: 10.1371/journal.pone.0113706

[8]	Liu H, Zhang Y, Li L, et al. Fascin actin-bundling protein 1 in human cancer: Promising biomarker or therapeutic target?[J]. Mol Ther Oncolytics, 2021, 20: 240-264. doi: 10.1016/j.omto.2020.12.014

[9]	Wurzer H, Hoffmann C, Al Absi A, et al. Actin cytoskeleton straddling the immunological synapse between cytotoxic lymphocytes and cancer cells[J]. Cells, 2019, 8(5): 463. doi: 10.3390/cells8050463

[10]	Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors[J]. Cancer Gene Ther, 2022, 29(1): 10-21 doi: 10.1038/s41417-021-00303-x

[11]	Zeyn Y, Harms G, Tubbe I, et al. Inhibitors of the actin-bundling protein fascin-1 developed for tumor therapy attenuate the t-cell stimulatory properties of dendritic cells[J]. Cancers (Basel), 2022, 14(11): 2738. doi: 10.3390/cancers14112738

[12]	Collignon E. Unveiling the role of cellular dormancy in cancer progression and recurrence[J]. Curr Opin Oncol, 2024, 36(2): 74-81. doi: 10.1097/CCO.0000000000001013